Remove 2017 Remove Documentation Remove Labelling
article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

This randomised, open label-controlled multicentre clinical trial was conducted across 21 sites in Spain from 2021 to 2023. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. 2017; 55(7):1998-2008. J Clin Microbiol.

article thumbnail

FDA OPDP Look Back at 2021 – The Yawning Gap

Eye on FDA

As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

However, as with drugs, dietary supplements require evidence that they are safe and that claims on product labels are truthful and not misleading. 20 Good manufacturing practice (GMP) Commission Directive (EU) 2017/1572 (which supplemented Directive 2001/83/EC) lays out the principles and guidelines of GMP in the EU. cited 2024May].

article thumbnail

Herbs and Supplements

RX Note

FDA requires the labels of all herbal supplements to include the complete list of ingredients and manufacturers must follow good manufacturing practices (GMP) to ensure that supplements are processed consistently and meet quality standards. Monitor therapy. Avoid in pregnancy.

article thumbnail

Pharma in Brief: The 2021 Year in Review

Pharma in Brief

Health Canada also consulted on proposed guidelines for the use of electronic media in prescription drug labelling (see here ). The major amendments to the PM(NOC) Regulations , made in 2017, continue to be interpreted by the FC and the FCA. Proposed amendments to the PM(NOC) Regulations were also introduced in 2021.

article thumbnail

Are Flame Retardant Toxins Contributing to Your Thyroid Condition?

The Thyroid Pharmacist

Several years ago, after reading research about all of the toxins commonly used in flame retardants (and learning about all of the many products in my home that contain these chemicals… somewhat of a shocking list), I looked at my mattress label, only to learn it contained one of the chief offenders. Labels (Furniture, Fabrics, and Carpet).

article thumbnail

NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms

Putting Patients First Blog

Manufacturer-Focused Input Question 30: Off-Label Use. CMS has appropriately highlighted the significance of off- label use information, providing a specific avenue for manufacturers to submit data on off-label uses supported by evidence-based guidelines listed in CMS-recognized Part D compendia. doi: 10.1016/j.jaad.2020.06.998